Le Lézard
Classified in: Health, Covid-19 virus
Subjects: LEG, AVO

HCLA Pushes for Inclusion of Good Samaritan Legislation in Pandemic Preparedness Reauthorization


WASHINGTON, June 13, 2023 /PRNewswire/ -- The Health Coalition on Liability and Access today announced its support for including the language contained in the Good Samaritan Health Professionals Act (H.R. 2819) as part of the pending reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA).

The Good Samaritan Health Professionals Act would protect medical volunteers from lawsuits during a large-scale disaster

The Good Samaritan Health Professionals Act would help protect medical volunteers from lawsuits during a large-scale disaster and ensure that vital health care services are available to disaster victims without altering liability laws that may currently exist in a particular state.

The PAHPA reauthorization is expected to consider several lessons learned from the COVID-19 pandemic and response, ensuring that our nation's health care systems and professionals are best equipped to respond to future pandemics and public health emergencies.

Today, inconsistencies in state laws result in a lack of health care professionals available to treat disaster victims, especially when applied to large-scale disasters that may cross state lines and affect patient care. The Good Samaritan Health Professionals Act mitigates the risks of meritless lawsuits that deter qualified individuals from volunteering, while respecting existing medical liability laws in individual states.

"On behalf of our coalition members, patients and medical professionals across the country, we strongly urge Congress to incorporate the Good Samaritan Health Professionals Act into legislation reauthorizing the Pandemic and All-Hazards Preparedness Act," said HCLA Chair Mike Stinson. "Addressing this issue now, before the next pandemic, natural disaster, or public health emergency occurs, makes it more likely that health care professionals will be willing and able to provide essential services to those most in need of critical care."

In addition to supporting the standalone Good Samaritan legislation and its inclusion in the Pandemic and All-Hazards Preparedness Act, the HCLA will continue to push for the introduction of this bipartisan legislation in the Senate and work to drive comprehensive reform to federal medical liability laws.

HEALTH CARE LIABILITY EXPERTS AVAILABLE FOR INTERVIEWS

For more details, visit www.hcla.org. The Health Coalition on Liability and Access is a national advocacy coalition representing physicians, hospitals, health care liability insurers, employers, health care providers and consumers. HCLA believes federal legislation is needed to bring fairness, timeliness and cost-effectiveness to America's medical liability system.

SOURCE Health Coalition on Liability and Access


These press releases may also interest you

at 16:15
GE HealthCare , is announcing that its Vice President and Chief Financial Officer, Jay Saccaro will be presenting at the following upcoming investor conferences. Bank of America Securities 2024 Healthcare Conference in Las Vegas ? May 14, 2024 at...

at 16:15
Revance Therapeutics, Inc. , today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT...

at 16:10
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the first quarter 2024 compared to the first quarter 2023. Product...

at 16:10
Twist Bioscience Corporation , a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended...

at 16:10
Vir Biotechnology, Inc. today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming...

at 16:10
Arcus Biosciences , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the...



News published on and distributed by: